Spots Global Cancer Trial Database for low grade glioma
Every month we try and update this database with for low grade glioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas | NCT01188096 | Brain Tumors | Poly ICLC | - 21 Years | Wake Forest University Health Sciences | |
| A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma | NCT04166409 | Low Grade Astro... Low Grade Gliom... Metastatic Low ... Metastatic Low ... | Biospecimen Col... Carboplatin Magnetic Resona... Quality-of-Life... Questionnaire A... Selumetinib Sul... Vincristine Sul... | 2 Years - 21 Years | National Cancer Institute (NCI) | |
| A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma | NCT02455245 | Low Grade Gliom... | Carboplatin Vincristine | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors | NCT03194906 | Glioma of Brain Craniopharyngio... Ependymoma Germ Cell Tumor | Memantine Placebo Cognitive Asses... | 6 Years - 21 Years | St. Jude Children's Research Hospital | |
| Nivolumab for Recurrent or Progressive IDH Mutant Gliomas | NCT03557359 | Gliomas | Nivolumab | 18 Years - | Columbia University | |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | NCT02684058 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Ipon... | Dabrafenib trametinib Carboplatin Vincristine | 12 Months - 17 Years | Novartis | |
| Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma | NCT01089101 | Low Grade Gliom... Recurrent Child... Recurrent Neuro... Recurrent Visua... Refractory Neur... Refractory Visu... | Biospecimen Col... Selumetinib | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | NCT03718767 | Glioma Glioblastoma High Grage Glio... Low Grade Gliom... Malignant Gliom... | Nivolumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma | NCT02286531 | Low Grade Gliom... | O-(2[18F]FLUORO... | 18 Years - | University Hospital, Toulouse | |
| A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma | NCT03871257 | Low Grade Gliom... Neurofibromatos... Visual Pathway ... | Carboplatin Magnetic Resona... Quality-of-Life... Questionnaire A... Selumetinib Sul... Vincristine Sul... | 2 Years - 21 Years | National Cancer Institute (NCI) | |
| FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma | NCT01089244 | Astrocytoma Oligoastrocytom... Oligodendroglio... | 18 Years - | Ludwig-Maximilians - University of Munich | ||
| (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas | NCT01281982 | Low Grade Gliom... Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... Oligoastrocytom... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | NCT02684058 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Ipon... | Dabrafenib trametinib Carboplatin Vincristine | 12 Months - 17 Years | Novartis | |
| ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas | NCT05609994 | Low Grade Gliom... | PEPIDH1M vaccin... | 18 Years - | Duke University | |
| A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas | NCT02209428 | Astrocytoma Oligodendroglio... Oligoastrocytom... | Temozolomide | 18 Years - 40 Years | Huashan Hospital | |
| Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | NCT03718767 | Glioma Glioblastoma High Grage Glio... Low Grade Gliom... Malignant Gliom... | Nivolumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas | NCT01188096 | Brain Tumors | Poly ICLC | - 21 Years | Wake Forest University Health Sciences | |
| Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs) | NCT00575796 | Glioma | Vinblastine Sul... | 1 Year - 18 Years | The Hospital for Sick Children | |
| Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG) | NCT02840409 | Low Grade Gliom... | Vinblastine Bevacizumab | 6 Months - 18 Years | The Hospital for Sick Children | |
| Angiogenic Profile and Non-invasive Imaging May Predict Tumor Progression of High Risk Group Low Grade Glioma (LGG) | NCT00137488 | Glioma | imaging and ang... | 18 Years - | AHS Cancer Control Alberta | |
| Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs) | NCT00575796 | Glioma | Vinblastine Sul... | 1 Year - 18 Years | The Hospital for Sick Children | |
| Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms | NCT04044937 | Intracranial Ne... Low Grade Gliom... Recurrent Gliob... Recurrent World... Recurrent WHO G... | F-18 Fluoroethy... Positron Emissi... | 3 Years - | University of California, San Francisco | |
| FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma | NCT01089244 | Astrocytoma Oligoastrocytom... Oligodendroglio... | 18 Years - | Ludwig-Maximilians - University of Munich | ||
| HyperSpectral Imaging in Low Grade Glioma | NCT04859725 | Low Grade Gliom... | Hyperspectral I... | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| Everolimus With and Without Temozolomide in Adult Low Grade Glioma | NCT02023905 | Low Grade Gliom... World Health Or... Oligodendroglio... Mixed Oligoastr... | Everolimus Temozolomide | 18 Years - | University of California, San Francisco | |
| Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma | NCT04553757 | Brain Neoplasm Low Grade Gliom... Seizure Disorde... | Survey Administ... | - | M.D. Anderson Cancer Center | |
| Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma | NCT01089101 | Low Grade Gliom... Recurrent Child... Recurrent Neuro... Recurrent Visua... Refractory Neur... Refractory Visu... | Biospecimen Col... Selumetinib | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas | NCT01229644 | Glioma | Crenolanib (CP-... | 18 Years - | Arog Pharmaceuticals, Inc. | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas | NCT02186262 | Low Grade Gliom... Malignant Gliom... | 18 Years - 80 Years | Turku University Hospital | ||
| ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas | NCT05609994 | Low Grade Gliom... | PEPIDH1M vaccin... | 18 Years - | Duke University | |
| Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients | NCT03849430 | Glioma of Brain | 18 Years - | Universitaire Ziekenhuizen KU Leuven | ||
| Intra-operative Variation in Size of Brain Tumors After Craniotomy | NCT04365647 | Brain Tumor, Pr... | 15 Years - 75 Years | Sheri Kashmir Institute of Medical Sciences | ||
| Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma | NCT04553757 | Brain Neoplasm Low Grade Gliom... Seizure Disorde... | Survey Administ... | - | M.D. Anderson Cancer Center | |
| Intra-operative Variation in Size of Brain Tumors After Craniotomy | NCT04365647 | Brain Tumor, Pr... | 15 Years - 75 Years | Sheri Kashmir Institute of Medical Sciences | ||
| Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas | NCT01229644 | Glioma | Crenolanib (CP-... | 18 Years - | Arog Pharmaceuticals, Inc. | |
| Nivolumab for Recurrent or Progressive IDH Mutant Gliomas | NCT03557359 | Gliomas | Nivolumab | 18 Years - | Columbia University | |
| HyperSpectral Imaging in Low Grade Glioma | NCT04859725 | Low Grade Gliom... | Hyperspectral I... | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors | NCT03194906 | Glioma of Brain Craniopharyngio... Ependymoma Germ Cell Tumor | Memantine Placebo Cognitive Asses... | 6 Years - 21 Years | St. Jude Children's Research Hospital | |
| Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy | NCT03952598 | Glioma Gliomas High Grade Glio... Malignant Gliom... Low Grade Gliom... | 3T MRI scanner | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| ROCOCO - Low Grade Glioma - Planning Study | NCT02607397 | Low Grade Gliom... | 18 Years - | Maastricht Radiation Oncology | ||
| Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial | NCT06132685 | Low Grade Gliom... Malignant Brain... Malignant Brain... Meningioma | Biospecimen Col... Computed Tomogr... Dexamethasone Magnetic Resona... Questionnaire A... | 18 Years - | Emory University | |
| A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma | NCT03871257 | Low Grade Gliom... Neurofibromatos... Visual Pathway ... | Carboplatin Magnetic Resona... Quality-of-Life... Questionnaire A... Selumetinib Sul... Vincristine Sul... | 2 Years - 21 Years | National Cancer Institute (NCI) | |
| Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma | NCT01089101 | Low Grade Gliom... Recurrent Child... Recurrent Neuro... Recurrent Visua... Refractory Neur... Refractory Visu... | Biospecimen Col... Selumetinib | 3 Years - 21 Years | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
